Teleflex Inc reported second-quarter 2026 results with revenue rising to $570.33M versus $442.53M a year earlier, while diluted EPS fell to $2.28 from $2.77 and net income declined to $99.69M from $122.58M.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$570.33M$442.53M28.9% | Net income²$99.69M$122.58M(18.7%) | Diluted EPS³$2.28$2.77(17.7%) |
¹ Reported as “Net revenues”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven primarily by the acquired VI Business and higher volumes of existing products, contributing approximately 29% growth in the quarter and ~31% year-to-date.
- Company is shifting channels through distributor-to-direct conversions and has announced strategic divestitures to exit OEM, Acute Care and IU product lines as part of portfolio realignment.
- Integration of the BIOTRONIK VI business expands Teleflex’s interventional portfolio with coronary and peripheral devices including drug-coated balloons and stents.
- Management is executing multi-year integration and divestiture restructuring plans to realign manufacturing and sales, with cost-reduction measures underway; tariffs, geopolitical risks and supply-chain actions remain material margin drivers.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.